Home » Archives by category » Clinical Trial News
Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine development company is carrying out the late-stage trial in the UK in partnership with the UK government’s Vaccines Taskforce. The phase 3 trial of NVX-CoV2373 will aim to enroll and […]

GENFIT begins phase 3 trial of elafibranor in primary biliary cholangitis

GENFIT has started the phase 3 ELATIVE clinical trial for evaluating the efficacy and safety of elafibranor for the treatment of primary biliary cholangitis (PBC). According to the French pharma company, ELATIVE is a randomized, double blind, placebo-controlled, global multicenter phase 3 study. Elafibranor is a dual PPAR alpha and delta agonist in primary biliary […]

Continue reading …
OliX Pharmaceuticals seeks FDA nod for phase 2a trial of OLX10010

OliX Pharmaceuticals, a South Korean pharma company, has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) seeking its consent to begin a phase 2a clinical trial for OLX10010 in reducing the recurrence of hypertrophic scars after scar revision surgery. The developer of RNAi therapeutics intends to assess the […]

Continue reading …
Millendo Therapeutics begins human trial of VMS drug candidate MLE-301

Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301, which is being developed for the treatment of menopausal women with vasomotor symptoms (VMS). VMS is known commonly as hot flashes and night sweats in menopausal women. The Michigan-based biopharma company has dosed the first subject in […]

Continue reading …
J&J begins phase 3 ENSEMBLE Covid-19 vaccine trial for JNJ-78436735

ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), which is being developed by its subsidiary – Janssen Pharmaceutical Companies. The US healthcare giant said that the ENSEMBLE vaccine trial has been initiated following positive interim results from its […]

Continue reading …
Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study

Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom from migraine attacks at 60 minutes and up to 48 hours. According to the US pharma giant, adults who were given Reyvow […]

Continue reading …
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia

SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]

Continue reading …
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]

Continue reading …
RELIEF-DPN-1 clinical trial : Lexicon begins patient dosing with LX9211

RELIEF-DPN-1 clinical trial : Lexicon Pharmaceuticals has started patient dosing in a phase 2 trial of LX9211 for the treatment of diabetic peripheral neuropathic pain. According to the Texan biopharma company, LX9211 is an oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). The RELIEF-DPN-1 clinical trial is a randomized, placebo-controlled, multi-center clinical study […]

Continue reading …
SAB Biotherapeutics begins phase 1b Covid-19 trial of SAB-185

SAB Biotherapeutics, a US biopharma company, said that the first patient in a phase 1b clinical trial of its investigational Covid-19 therapeutic SAB-185 has been dosed. The early-stage trial is assessing the safety and pharmacological activity of SAB-185 in Covid-19 patients. SAB-185, which was generated from a subunit of the SARS-CoV-2 Wuhan strain, has delivered […]

Continue reading …
Page 1 of 17123Next ›Last »